NASDAQ:GRDX Entero Therapeutics Q3 2026 Earnings Results & Report $3.24 -0.21 (-5.94%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$3.26 +0.01 (+0.46%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Entero Therapeutics reported Q3 2026 earnings on November 16, 2026. The company reported EPS of -$0.27, while revenue was $38.11 thousand. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market Opens Entero Therapeutics EPS ResultsActual EPS-$0.27Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEntero Therapeutics Revenue ResultsActual Revenue$38.11 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Entero Therapeutics Q3 2026 Earnings FAQ Did Entero Therapeutics beat earnings estimates for Q3 2026? Entero Therapeutics (NASDAQ:GRDX) reported earnings of -$0.27 per share for Q3 2026. The report was announced on Monday, November 16, 2026. What was Entero Therapeutics' revenue for Q3 2026? Entero Therapeutics reported revenue of $38.11 thousand for Q3 2026. Entero Therapeutics Earnings HeadlinesEntero Therapeutics (NASDAQ:GRDX) Upgraded to Hold at Wall Street ZenNovember 21 at 1:06 AM | americanbankingnews.comGridAI Technologies Signs Definitive Agreement to Acquire Pronghorn Resources, Establishing Major Wyoming Owned-Natural Gas and Multi-Gigawatt AI Power Infrastructure Platform Targeting Initial Power Delivery in 2027November 13, 2026 | globenewswire.comSee More Entero Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Entero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entero Therapeutics and other key companies, straight to your email. Email Address About Entero TherapeuticsEntero Therapeutics (NASDAQ:GRDX) is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its research has focused on therapies designed to act in the digestive tract, including candidates for celiac disease, inflammatory bowel disease and exocrine pancreatic insufficiency. Its pipeline has included latiglutenase, an oral enzyme therapy intended to break down gluten in the gut, and adrulipase, an oral enzyme replacement candidate for people with exocrine pancreatic insufficiency. These are investigational products and are not approved treatments. The company was formerly known as First Wave BioPharma before adopting the Entero Therapeutics name. Its work has centered on developing drug candidates rather than marketing approved medicines.View Entero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.